Drug Trial Radar · NCT04374877
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Apr 22, 2020
Primary completion
May 28, 2025
Study completion Jun 5, 2025
Sponsor
- Lead sponsor
- Coherus Oncology, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- May 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Conditions
- Advanced Solid Tumor
- Clear Cell Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Non-small Cell Lung Cancer
Interventions
CHS-388Drug
CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.
PembrolizumabDrug
Pembrolizumab by intravenous (IV) infusion
ToripalimabDrug
Toripalimab by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Part A] Dose Limiting Toxicity (DLT)Time frame: Assessed during first 28 days of treatment
- [Part B] Confirmed objective response rate (ORR)Time frame: Up to 24 months
- [Part C] DLTTime frame: Assessed during first 21 days of treatment
- [Part C] Summary of adverse events (AEs) based on treatment emergent AEs (TEAEs)Time frame: Up to 24 months
- [Part C -NSCLC Cohort] Objective response rate (ORR)Time frame: Up to 24 months
- [Part D] Objective response rate (ORR)Time frame: Up to 24 months
Locations
23 sites in 3 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
University of Southern California (USC) - Norris Comprehensive Cancer Center
Los Angeles, California
UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center
San Francisco, California
University of Miami Leonard M. Miller School of Medicine (UMMSM)
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan Health System (UMHS)
Ann Arbor, Michigan
Washington University School of Medicine - St. Louis
St Louis, Missouri
Roswell Park
Buffalo, New York
Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)
New York, New York
Cleveland Clinic
Cleveland, Ohio
University of Oklahoma Health Sciences Center (OUHSC) - Stephenson Cancer Center
Oklahoma City, Oklahoma
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI))
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center (VUMC)
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
The University of Texas - MD Anderson Cancer Center
Houston, Texas
South Texas Accelerated Research Therapeutics
San Antonio, Texas
University of Washington
Seattle, Washington
National University Hospital
Singapore, Singapore
National Cancer Center Singapore (NCCS)
Singapore, Singapore
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.